Doxorubicin

Generic Name: Doxorubicin

Brand Names: Adriamycin, Doxil, Myocet, Caelyx pegylated liposomal, Zolsketil pegylated liposomal, Myocet liposomal (previously Myocet), Celdoxome pegylated liposomal

Drug Type: Small Molecule

Chemical Formula: C_₂₇H_₂₉NO_₁₁

CAS Number: 23214-92-8

Unique Ingredient Identifier: 80168379AG

Background: Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius along side with daunorubicin, another cytotoxic agent, in 1970. Although they both have aglyconic and sugar moieties, doxorubicin's side chain terminates with a primary alcohol group compared to the methyl group of daunorubicin. Although its deta...

Indication: Doxorubicin is indicated for the treatment of neoplastic conditions like acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin and non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms’ tumor, metastatic neuroblastoma, metastatic soft tissue and bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinom...

Associated Conditions: AIDS-related Kaposi's Sarcoma, Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Advanced Endometrial Cancer, Advanced Ovarian Cancer, Breast Cancer, Hodgkin's Lymphoma, Metastatic Bone Sarcomas, Metastatic Breast Cancer, Metastatic Soft Tissue Sarcoma, Metastatic Thyroid Cancer, Metastatic Urothelial Cancer, Multiple Myeloma (MM), Mycosis Fungoides (MF), Non-Hodgkin's Lymphoma (NHL), Sezary Syndrome, Waldenström's Macroglobulinemia (WM), Advanced Thymoma, Advanced uterine sarcoma, Metastatic Bronchogenic Carcinoma, Metastatic Gastric carcinoma, Metastatic Neuroblastoma, Metastatic Ovarian carcinoma, Metastatic Wilms' tumor

Associated Therapies: -

Clinical Trials

Combination Chemotherapy in Treating Patients With Aggressive Non-Hodgkin's Lymphoma

Phase 3

Completed

Conditions: Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2013-06-26

Lead Sponsor: Lymphoma Trials Office

Target Recruit Count: 310

Registration Number: NCT00005867

Locations: 🇬🇧
Horton Hospital, Banbury, England, United Kingdom
🇬🇧
Hinchingbrooke Hospital, Huntingdon, England, United Kingdom
🇬🇧
Hull Royal Infirmary, Hull, England, United Kingdom

and more 43 locations

Doxorubicin and Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Soft Tissue Sarcoma

Phase 2

Completed

Conditions: Sarcoma

First Posted Date: 2003-01-27

Last Posted Date: 2013-06-24

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00052390

Locations: 🇺🇸
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Huntsman Cancer Institute, Salt Lake City, Utah, United States
🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Inhaled Doxorubicin in Treating Patients With Primary Lung Cancer or Lung Metastases

Phase 1

Completed

Conditions: Lung Cancer
Metastatic Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2013-06-19

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00004930

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸
Arthur G. James Cancer Hospital - Ohio State University, Columbus, Ohio, United States

Phase II Bevacizumab + Tax In Advanced Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Biological: bevacizumab
Drug: cyclophosphamide
Drug: docetaxel
Drug: doxorubicin hydrochloride
Procedure: adjuvant therapy
Procedure: conventional surgery
Procedure: neoadjuvant therapy
Radiation: radiation therapy

First Posted Date: 2003-01-27

Last Posted Date: 2013-06-17

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 49

Registration Number: NCT00027885

Locations: 🇺🇸
UH-Southwest, Middleburgh Heights, Ohio, United States
🇺🇸
UH-Green Road, South Euclid, Ohio, United States
🇺🇸
Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

and more 2 locations

Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Acute Lymphoblastic Leukemia

Phase 3

Completed

Conditions: Leukemia
Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2013-06-12

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 392

Registration Number: NCT00002700

Locations: 🇸🇰
Institute of Hematology & Transfusiology, University Hospital, Bratislava, Slovakia
🇧🇪
Hopital Universitaire Erasme, Brussels, Belgium
🇧🇪
Universitair Ziekenhuis Antwerpen, Edegem, Belgium

and more 41 locations

Tipifarnib, Doxorubicin, and Cyclophosphamide in Treating Women With Locally Advanced Breast Cancer

Phase 2

Completed

Conditions: Inflammatory Breast Cancer
Stage II Breast Cancer
Stage IIIA Breast Cancer
Stage IIIB Breast Cancer
Stage IIIC Breast Cancer

Interventions: Drug: doxorubicin hydrochloride
Drug: cyclophosphamide
Drug: tipifarnib
Biological: filgrastim
Procedure: therapeutic conventional surgery
Other: laboratory biomarker analysis

First Posted Date: 2003-01-27

Last Posted Date: 2013-06-06

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 62

Registration Number: NCT00049114

Locations: 🇺🇸
Albert Einstein College of Medicine, Bronx, New York, United States

ONCONASE Plus Doxorubicin Versus Doxorubicin Alone For Patients With Malignant Pleural or Peritoneal Mesothelioma Who Have Had No More Than One Prior Chemotherapy Regimen

Phase 3

Conditions: Malignant Mesothelioma

Interventions: Drug: doxorubicin hydrochloride
Drug: ranpirnase

First Posted Date: 2003-01-27

Last Posted Date: 2013-11-06

Lead Sponsor: Alfacell

Target Recruit Count: 300

Registration Number: NCT00003034

Locations: 🇩🇪
Asklepios Klinik St. Georg, Hamburg, Germany
🇺🇸
CCOP - Duluth, Duluth, Minnesota, United States
🇺🇸
Spectrum Health Hospital - Butterworth Campus, Grand Rapids, Michigan, United States

and more 16 locations